<DOC>
	<DOC>NCT01432717</DOC>
	<brief_summary>The purpose of this study is to find out whether ACE-536 can be safely given to patients. This study will also look to see if ACE-536 increases red blood cells, the cells that carry oxygen in the body.</brief_summary>
	<brief_title>Study of ACE-536 in Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<criteria>Key Postmenopausal women Body Mass Index (BMI) of 20 32 kg/m2. Key History of hypertension Subject has received any erythropoiesis stimulating agents (e.g., Epogen, Procrit, Aranesp, etc.) within 6 months prior to Day 1 History of clinically significant cardiac, endocrine, hematologic, hepatic, immune, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other disease Surgery within 3 months (other than minor cosmetic surgery or minor dental procedures) Subject has received treatment with another investigational drug, or approved therapy for investigational use within 1 month prior to Day 1, or if the halflife of the previous product is known, within 5 times the halflife prior to Day 1, whichever is longer</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>